Pulmonary inflammatory myofibroblastic tumor in a breast cancer patient, a rare presentation
Article Sidebar
Main Article Content
Abstract
Inflammatory myofibroblastic tumor (IMT), a benign and rare neoplasm, of mesenchymal origin, pseudoarcomatous, is responsible for about 0.7% of all neoplastic presentations in the pulmonary region, being the most frequent cause of pulmonary nodules in pediatric patients, approximately 50% of the presentations. Thus, the present study aims to report a rare case of IMT in the lung site in a 31-year-old patient undergoing treatment for breast cancer, according to a literary review, relating the data according to the clinical presentation. Due to scarce documentation in the medical literature, no cases were found similar to the one described in relation to the reported oncological primary condition of the patient, making the present case a clinical challenge in modern medical practice.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Gentile JKA, Ruiz DF, Moricz A, et al. Tumor miofibroblástico inflamatório da vesícula biliar: relato de caso. GED gastroenterol. Endosc Dig. 2014;33(3):112-4.
Oliveira RF, Couto RWG, Dias AFM, et al. Tumormiofibroblástico. Urominas. 2017;1(4):37-40.
Pinilla I, Herrero Y, Torres MI, et al. Tumor inflamatório miofibroblástico pulmonar. Radiología, 2007;49(1):53- 5. doi:10.1016/s0033-8338(07)73718-9.
Ereño C, López JI, Grande J, et al. Inflammatory myofibroblastic tumor of the larynx. J Laryngol Otol. 2001;115(10):856-8.
Arber DA, Weiss LM, Chang KL. Detection of Epstein-Barr virus in inflammatory pseudotumor. Semin Diagn Pathol. 1998;15(2):155-60. PMid:9606806.
Fernández Villar A, Mosteiro Añón M, Corbacho Abelaira D, et al. Pulmonary inflammatory pseudotumor: report of 2 cases and review of the literature [Article in Spanish]. An Med Interna. 1997;14(9):469-72.
Donner LR, Tompler RA, White, RR. Progression of inflammatory myofibroblastic tumor (inflammatory pseudotumor) on soft tissue into sarcoma after several recurrences. Hum Pathol. 1996;27(10):1095-8. doi:10.1016/S0046-8177(96)90291-9.
Powell CL, Holzbeierlein JM, Wetzel L, et al. Inflammatorymyofibroblastic tumor: a case study. Urol Case Reports. 2014;2(5):173-175. doi:10.1016/j.eucr.2014.05.010.
Tsuzuki T, Magi-Galluzzi C, Epstein JI. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol. 2004;28(12):1609-14.
Berardi RS, Lee SS, Chen HP. Inflammatory pseudotumors of the lung. Surg Gynecol Obstet. 1983;156(1):89-96.
Hedlung GL, Navoy JF, Galliani CA, et al. Aggressive manifestations of inflammatory pulmonary pseudotumor in children. Pediatr Radiol. 1999;29:112-6. doi:10.1007/s002470050553.
Verbeke JIM, Verberne AAP, Hollander JD, et al. Inflammatory myofibroblastic tumour of the lung manifesting as progressive atelectasis. Pediatr Radiol. 1999;29:816-9. doi:10.1007/s002470050703.
Schoffski P, Sufliarsky J, Gelderblom H, et al. Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". In: Proc Annu Meet Am Assoc Cancer Res; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78 (13 Suppl):Abstract nr CT045.